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Background: Despite the overall high degree of response to pharmacotherapy, consensus is lacking on how
to judge clinical response or define optimal treatment/remission when treating adults with attention-deficit/
hyperactivity disorder (ADHD). This study examined clinical response and symptomatic remission in analyses of
2 studies of lisdexamfetamine dimesylate (LDX) in adults with ADHD.
Methods: In a 4-week, double-blind, forced-dose trial, adults with ADHD were randomized to LDX 30, 50, and
70 mg/day (mg/d) or placebo. In a second, open-label, follow-up trial, adults entering from the 4-week study
were titrated to an “optimal” LDX dose (30 mg/d [n=44], 50 mg/d [n=112], and 70 mg/d [n=171]) over
4 weeks, and maintained for 11 additional months. The ADHD Rating Scale IV (ADHD-RS-IV) with adult
prompts and the Clinical Global Impressions-Improvement (CGI-I) scale assessed efficacy. Clinical response was
defined, post hoc, as ≥30% reduction from baseline in ADHD-RS-IV and CGI-I rating of 1 or 2; symptomatic
remission was defined as ADHD-RS-IV total score ≤18. Log rank analysis examined overall significance among
the treatment groups in time to response or remission.
Results: Four hundred and fourteen participants in the 4-week study and 345 in the open-label, extension
study were included in the efficacy populations. All LDX groups improved by ADHD-RS-IV and CGI-I scores in
both studies. In the 4-week study (n=414), 69.3% responded and 45.5% achieved remission with LDX (all
doses); 37.1% responded and 16.1% achieved remission with placebo; time (95% CI) to median clinical
response (all LDX doses) was 15.0 (15.0, 17.0) days and to remission was 31.0 (28.0, 37.0) days (P<.0001
overall). In the open-label study, with LDX (all doses), 313 (95.7%) and 278 (85.0%) of 327 participants with
evaluable maintenance-phase data met criteria for response and remission, respectively. Of participants who
completed dose optimization, 75.2% remained responders and 65.7% remained in remission in the 12-month
study. Overall, 285 (82.6%) and 227 (65.8%) of 345 participants were responders and remitters, respectively, at
their final visits.
Conclusion: In the long-term study, with open-label, dose-optimized LDX treatment, most adults with ADHD
achieved clinical response and/or symptomatic remission; almost two-thirds maintained symptomatic remission
over the remaining 11 months.
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Attention-deficit/hyperactivity disorder (ADHD) is a com-
mon neurobehavioral condition that is estimated to affect
5% to 10% of youths worldwide and approximately 4.4% of
adults in the United States [1,2]. Clinical trials of stimulant
pharmacotherapy in adults with ADHD indicate high
levels of efficacy. Significantly improved ADHD symptom
scores (versus placebo) based on randomized, placebo-
controlled trials using long-acting formulations of either
methylphenidate (MPH) [3,4] or amphetamines have been
reported [5,6].
Despite the overall high degree of treatment response,
there are very limited guidelines for how to judge clinical
response or how to define optimal treatment/remission
when treating adults with ADHD [7]. Meta-analyses indi-
cate effect sizes (relative to placebo) of approximately 0.7
with long-acting psychostimulant medications in adults
with ADHD [8]. ADHD symptom scores, based on the
ADHD Rating Scale IV (ADHD-RS-IV) [9] and other
similar scales, as well as effect size estimates have value
but do not indicate what percentage of participants may
be expected to improve, when improvement may become
apparent, and whether improvements persist. Neither do
they address whether participants continue to meet diag-
nostic criteria, particularly criteria related to functional
impairments associated with ADHD symptoms.
Few clinical trials have assessed ADHD treatment effi-
cacy in terms of clinical response, and, to date, no trials in
adults (to our knowledge) have described rates of symp-
tomatic remission. Throughout the broad field of psych-
iatry, numerous definitions of “response” have been
proposed, all generally aimed at defining individuals who
show clinically apparent improvement to a definitive inter-
vention but who still experience some degree of symptoms
[10,11]. As reviewed by Steele et al. [12] and based on vari-
ous clinical trials of participants with ADHD, response to
treatment has been operationally defined as improvement
from baseline of 25% to 30% in rating scales such as the
ADHD-RS-IV or Swanson, Nolan, and Pelham, Version
IV (SNAP)-IV. Inherent to this definition of treatment
response is that individuals may continue to have symp-
toms of the disorder because percent reductions do not
account for baseline severity levels. For that reason, a de-
finition of clinical response that is both a composite of apercent reduction in symptoms (eg, a 30% improvement
in symptom levels from baseline), as well as a second
measure of clinical improvement (eg, Clinical Global
Impressions-Improvement [CGI-I] [13] of 1 [very much
improved] or 2 [much improved]) may be considered a
more meaningful measure. Moreover, it has been reported
that an approximate 10- to 15-point change or a percent
change of approximately 25% to 30% in ADHD-RS-IV
scores corresponded to a 1-level change on the CGI-I [14].
Three types of remission have also been proposed for
ADHD: syndromatic, symptomatic, and functional [15].
Syndromatic remission is defined as “failing to meet the
full diagnostic criteria for ADHD” [15] and was origi-
nally described for bipolar disorder by Keck et al. [16] as
syndromatic recovery. Symptomatic remission is defined
as having fewer than 5 symptoms, the number of symp-
toms required for a subthreshold ADHD diagnosis [15].
Functional remission is defined as “the loss of partial
diagnostic status plus functional recovery” [15]. In cli-
nical practice, this is likely to be thought of as successful
treatment, where the participant no longer exhibits the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSM-IV-TR) behavioral
diagnostic criteria for ADHD [17,18]. As reviewed by
Keck and colleagues, functional recovery indicates that a
patient has attained premorbid levels of functioning
(eg, work and psychosocial) for a defined extended
period of time [16]. Although not assessed in this study,
functional outcome measures in conjunction with those
of clinical response and symptomatic remission used to
evaluate ADHD symptoms may be clinically relevant
assessments for managing and treating ADHD.
Researchers have attempted to objectively define cli-
nical response and symptomatic remission using scale-
based cutoff thresholds [18,19]. In the Multimodal
Treatment Study of Children With ADHD, success or
“excellent response” was defined as a SNAP-IV mean
per-item score ≤1, indicating symptom ratings of “not at
all” to “just a little” and a severity level below the ADHD
diagnostic threshold [18]. Similarly, a total score of ≤18
on the ADHD-RS-IV, which scores each of the 18-item
DSM-IV-TR criteria, defines an ADHD population that
is rated on average by the clinician as mildly sympto-
matic. To define symptoms, each item was rated on a
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(often); and 3 (very often) [9]. On average, a score of 1
(ie, “sometimes”) across the 18-item scale has been
proposed as defining symptomatic remission for partici-
pants with combined-type ADHD [12]. This cut off
score of ≤18 indicates loss of ADHD symptom status
such that the clinician considers the individual with
ADHD as no longer exhibiting DSM-IV-TR symptom
criteria [12]. The cut off for symptomatic remission is
having clinically minimal (eg, “sometimes ill” on the
ADHD-RS-IV and “just a little ill” on SNAP-IV) or no
symptoms (eg, “never or rarely” on the ADHD-RS-IV
and “not at all” on SNAP-IV), which is considered in the
range of a matched control group without ADHD [12].
In the current investigation, rates of clinical response
and symptomatic remission were examined based on
post hoc analysis of efficacy data from 2 adult clinical
trials of lisdexamfetamine dimesylate (LDX) [5,20]. In a
short-term (4-week), randomized, placebo-controlled
forced-dose escalation trial, ADHD-RS-IV clinician-rated
symptom scores were significantly reduced (P≤.001) in
all LDX groups (30, 50, and 70 mg/day [mg/d]) com-
pared with placebo at weeks 1 to 4 and endpoint, and
CGI-I ratings were significantly reduced at endpoint
(P≤.001) [5]. A 12-month, open-label extension study
enrolled eligible participants from the preceding short-
term LDX trial. Results of the extension study demon-
strated that ongoing LDX treatment was associated with
a significant reduction in ADHD symptom scores from
baseline of the prior study at all postbaseline visits and
at endpoint (P<.001) [20]. In the current post hoc ana-
lysis, maintenance of clinical response and symptomatic
remission during the 12-month open-label treatment
was evaluated. The main goal of examining these post
hoc analyses was to assess how useful these criteria are
in providing additional clinically relevant information to
evaluate the use of LDX in short- and long-term ADHD
treatment.
Methods
Methods common to both clinical trials
Detailed methodology for both the short-term study and
the follow-up, long-term extension study of LDX has
been previously reported [5,20]. The studies were con-
ducted from May to November 2006 and July 2006 to
November 2007, respectively, at 44 sites in the United
States, and were performed in accordance with the Dec-
laration of Helsinki and the International Conference on
Harmonization Guidelines for Good Clinical Practice.
Institutional Review Boards at each site approved the
protocol and conduct of the studies. All participants
provided written informed consent. Both studies en-
rolled adults with a primary diagnosis of ADHD, based
on the DSM-IV-TR criteria for the predominantlyinattention subtype or the predominantly hyperactive/
impulsive and combined subtypes.
For both studies, the primary outcome was change in
ADHD-RS-IV with adult prompts total score from base-
line at endpoint. ADHD-RS-IV scores were measured at
each weekly visit in the short-term study [5], and at
weekly and monthly visits during the extension study
[20]. The ADHD-RS-IV contains 18 items corresponding
to the criteria for an ADHD diagnosis described in the
DSM-IV-TR. Secondary efficacy measures in both studies
included the CGI-Severity (CGI-S) scale assessed at
baseline of the short-term study (carried forward for the
extension study), and the CGI-I scale assessed at all
postbaseline visits in both studies. The CGI-S is used to
rate the severity of symptoms on a 7-point scale ranging
from 1 (normal, not at all ill) to 7 (among the most
severely ill participants) at baseline. Symptom improve-
ment was rated by the clinician on the CGI-I using a
7-point scale ranging from 1 (very much improved) to
7 (very much worse).
Safety assessments for both studies included spontan-
eously reported adverse events (AEs), vital signs, electrocar-
diograms (ECGs), routine clinical laboratory monitoring,
and physical examinations (eg, height and weight), as previ-
ously reported [5,20]. Treatment-emergent AEs (TEAEs)
referred to events with onset after the first date of treat-
ment and no later than 3 days following termination of
treatment.Short-term placebo-controlled study
In the 4-week, multicenter, placebo-controlled, double-
blind, parallel-group, forced dose-escalation trial, [5] parti-
cipants were randomly assigned in a 2:2:2:1 ratio to receive
oral LDX (30, 50, or 70 mg/d) or placebo. Study phases
included screening/washout, baseline randomization and
measures, and a 4-week double-blind evaluation of LDX
versus placebo. All participants initiated treatment with
the 30-mg/d dose; participants assigned the higher doses
initiated treatment with 30 mg/d, and the dose was
increased in 20-mg increments, as assigned, at weekly
intervals to 50 mg/d or 70 mg/d. Inclusion and exclusion
criteria have been previously reported [5]. Briefly, key
inclusion criteria included adults (≥18 to 55 years of age)
diagnosed with ADHD according to DSM-IV-TR criteria
with a baseline ADHD-RS-IV score ≥28. Exclusion criteria
included individuals with comorbid psychiatric disorders;
history of seizures, hypertension, tic disorder; Tourette
disorder; pregnant or lactating women; positive urine drug
result at screening or baseline; current medication use that
might confound the results of the study or increase risk
to the participant; clinically significant ECG; and any
concurrent chronic or acute illness, or unstable medical
condition.
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Participants enrolled in the short-term study for ≥2 weeks
without AEs that would preclude continued treatment
with LDX were eligible to participate in the long-term
(12-month), open-label, single-arm study [5,20]. Baseline
vital signs, ECG findings, and weight were carried over
from the final visit of the previous study for participants
enrolling within 7 days of finishing that study; otherwise,
participants underwent a full screening and washout
period with baseline assessments. Efficacy measures for all
participants were carried forward from baseline of the
prior trial. LDX treatment was initiated at 30 mg/d
and, based on clinical judgment, could be increased or
decreased in 20-mg increments at subsequent visits to
achieve optimal efficacy and tolerability over a 4-week
titration period. Adults were titrated to an “optimal” LDX
dose (30 mg/d [n=44], 50 mg/d [n=112], and 70 mg/d
[n=171]) over 4 weeks. Treatment was then maintained
for up to 11 months during which time dosage could be
adjusted up or down by 20-mg increments at monthly
study visits, as deemed appropriate by the study investiga-
tor. The minimum dose was 30 mg/d while the maximum
was 70 mg/d.
Clinical response and symptomatic remission analyses
Table 1 summarizes post hoc analysis criteria for clinical
response and symptomatic remission [9,12,18]. In the
long-term trial, re-emergence of symptoms following
clinical response or symptomatic remission was defined
as failure to meet the criteria for response or remission
at a later visit. Once having failed to meet such criteria,
those participants were removed from further analysis.
Maintenance of clinical response or symptomatic remis-
sion was evaluated among participants who met re-
sponse/remission criteria and completed the 4-week
dose-optimization phase in the long-term trial. It was
decided that the study design of the short-term trial,Table 1 Definitions and criteria for post hoc analysis of clinic
Terms Definitions and Criteri
Clinical response ≥30% reduction in ADH
Symptomatic remission ADHD-RS-IV total score
Time to median clinical response or
symptomatic remission
Time by which half the
remission
Loss of clinical response or symptomatic
remission status
Failure to meet criteria f
status at a previous visit
Maintenance of clinical response or
symptomatic remission at endpoint
4-week trial:
Participants meeting crit
enrolled at endpoint, an
Long-term trial:
Participants meeting crit
and meeting the criteria
aRelative to baseline ADHD-RS-IV total score in the 4-week trial.
Abbreviations: ADHD-RS-IV = Attention-Deficit/Hyperactivity Disorder Rating Scale IVbecause of the 4-week duration and the forced-dose
titration schedule, was not suited for an analysis of
maintenance of response or remission. Similarly, because
the study design of the long-term trial did not require a
defined washout period for those participants directly
rolling over from the short-term study, there is a poten-
tial for carryover effect. Therefore, short-term data were
used for the analysis of time to median clinical response
or symptomatic remission, and long-term data were
used for the analysis of time to median loss of clinical
response or symptomatic remission.
Statistical analysis
Efficacy analyses were performed on the intention-to-
treat population, also referred to as the efficacy popula-
tion, defined in the 4-week study as all randomized and
treated participants with a primary efficacy assessment
at baseline and at least once postrandomization, and in
the long-term study as those with at least one postbase-
line primary efficacy assessment. Differences among all
LDX dose groups in the 4-week study for time to me-
dian clinical response or symptomatic remission were
analyzed post hoc with a log-rank statistic test. No
adjustments for multiple comparisons were performed
on the optimal-dose group for statistical comparisons.
Assessment of time to median first clinical response or
symptomatic remission and of time to median first loss
of clinical response or symptomatic remission was per-
formed using survival analysis [21]. In the short-term
study, percentages of participants achieving clinical
response or symptomatic remission and time to median
first clinical response or symptomatic remission from
baseline were calculated for the efficacy population. In
the long-term study, percentages of participants losing
clinical response or symptomatic remission at any point
during the maintenance phase of the study were calcu-
lated from the start date of the study. Only participantsal response and symptomatic remission [12,18]
a
D-RS-IV with adult prompts total scorea and a CGI-I rating of 1 or 2
≤18 (average per-item score ≤1)
original sample achieves criteria for clinical response or symptomatic
or clinical response or symptomatic remission after having achieved that
eria for clinical response or symptomatic remission at postbaseline visits,
d meeting criteria without interruption
eria for clinical response or symptomatic remission at postbaseline visits
without interruption up to endpoint
; CGI-I=Clinical Global Impressions-Improvement.
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mission status within the dose-titration phase and who
continued into the maintenance phase of the study were
included in this analysis. Survival analysis documents
the first occurrence of an event and cannot take into
consideration participants who lose clinical response or
symptomatic remission at one time point but subse-
quently regain that status. Participants who discontinued
the study or who reached study endpoint while in clin-
ical response or symptomatic remission were censored.
Loss of symptomatic remission status did not preclude
continuing in the post hoc analysis as a clinical re-
sponder. Specifically, it is important to note that survival
analyses conducted in this study were designed to only
examine loss of clinical response and symptomatic re-
mission, while censoring was defined in these analyses
as removing a participant who did not have the event at
their last study visit.
Results
Short-term study clinical response and symptomatic
remission outcomes
A total of 420 participants were randomized; 414 partici-
pants were included in the efficacy population. Baseline
demographic and clinical characteristics by treatment
group (LDX 30, 50, or 70 mg/d or placebo) have been
described in detail previously [5]. Briefly, mean (SD) base-
line ranges for age were 34.2 (10.0) years to 35.8 (10.5)
years, for weight were 173.1 (37.8) pounds to 181.3 (39.1)
pounds, and for height were 67.4 (3.7) inches to 67.9 (3.9)
inches and were comparable among the LDX and placebo
treatment groups in the safety population. Most partici-
pants were Caucasian (77.4%-88.5%), and slightly more
than half were men (51.6%-56.4%). In accordance with
enrollment criteria, all participants exhibited ADHD
symptoms at baseline that were at least moderate in seve-
rity (eg, CGI-S=4: 30%-44%, CGI-S >4: 56%-70%).
Table 2 summarizes the proportions of participants




Clinical response, n (%) 77 (67.0)




Symptomatic remission, n (%) 51 (44.3)




aRelative to baseline time to median clinical response in the 4-week trial.
bSee Figure 1.
cSee Figure 2.
Abbreviations: d day, CI confidence interval, LDX lisdexamfetamine dimesylate, NA nremission at any time during the study and the time to
median (95% confidence interval [CI]) clinical response
and symptomatic remission from baseline by which
these criteria were met. Of 352 participants treated with
LDX (all doses combined), 244 (69.3%) responded to
treatment (vs 23 of 62 [37.1%] in the placebo group);
based on Kaplan-Meier analysis, time to median (95%
CI) clinical response was 15.0 (15.0, 17.0) days for all
LDX dosage groups at that point in time (overall log
rank P<.0001) (Figure 1 and Table 2). Although the do-
sing was not the same over time, a total of 160 (45.5%)
participants given LDX (all doses combined) achieved
symptomatic remission (vs 10 of 62 [16.1%] in the
placebo group); based on Kaplan-Meier analysis, time
to median (95% CI) symptomatic remission was 31.0
(28.0, 37.0) days for all LDX doses (overall log rank
P<.0001) (Figure 2 and Table 2).
Long-term study clinical response and symptomatic
remission outcomes
As previously reported, [20] the long-term open-label
study enrolled 349 adults; 337 (96.6%) within 7 days
of the end of the short-term study [5]. The efficacy
population consisted of 345 participants (n=296, LDX;
n=49, placebo, in the prior study), has been described
previously [20] and was generally comparable to that
in the short-term trial. Of the 345 participants in the
efficacy population, 325 (94.2%) participants met cri-
teria for clinical response at any point during the
study, and 286 (82.9%) participants met criteria for
symptomatic remission from baseline. Overall, 285 of
345 (82.6%) participants met criteria for clinical
response and 227 of 345 (65.8%) participants met
criteria for symptomatic remission at their final study
visit (ie, end of study/or early termination [ET]).
Eighteen (5.2%) participants of the 345 in the efficacy
population were excluded from the time to median
events analysis in the maintenance phase because of dis-
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Treatment Groups: 30 mg/d LDX 50 mg/d LDX 70 mg/d LDX All Doses Placebo***
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Figure 1 Kaplan-Meier plot: time to median clinical response from baseline in the short-term study by LDX treatment group (efficacy
population, n=414). Log rank P-value: <.0001. P-value indicates overall significant effect among the treatment groups and was not specifically
tested between any individual dose groups. Abbreviations: d=day; LDX=lisdexamfetamine dimesylate.
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A total of 327 participants completed dose titration,
entered the maintenance phase of the study, and had
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Figure 2 Kaplan-Meier plot: time to median symptomatic remission f
(efficacy population, n=414). Log rank P-value: <.0001. P-value indicates
specifically tested between any individual dose groups. Abbreviations: d=dOf the 327 participants who completed dose titration,
315 participants continued into the third month or there-
after and were evaluable for a subsequent change in dose.
The percent of participants optimized to each LDX dose,
among participants who completed dose optimization5 3530 40
g/d LDX All Doses Placebo***
* * * * * * *



























rom baseline in the short-term study by LDX treatment group
overall significant effect among the treatment groups and was not
ay; LDX=lisdexamfetamine dimesylate.
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the treatment dose at the end of dose titration was not ne-
cessarily the dose when clinical response or symptomatic
remission was attained. Of the 148 participants titrated to
either 30 mg/d (n=40) or 50 mg/d (n=108) LDX at the
start of the maintenance phase, 54 (36.5%) participants
had a dose increase. Sixty-three (22.9%) of 275 partici-
pants, titrated to either 50 mg/d (n=108) or 70 mg/d
(n=167) LDX at the start of the dose-maintenance phase
had a dose decrease; 113 participants had either an
increase or a decrease from their titrated dose.
Of the 327 participants with evaluable maintenance-
phase data, 313 (95.7%) met criteria for clinical response
during the study with LDX (all doses) treatment (Table 3
and Figure 4). Moreover, 278 (85.0%) of these 327 parti-
cipants met criteria for symptomatic remission during
the study with LDX (all doses) treatment (Table 3 and
Figure 5).
There were 278 participants who completed the dose-
optimization phase and were classified as responders at
entry to the maintenance phase; 209 (75.2%) participants
did not experience a loss of clinical response during the
maintenance phase or at each of their subsequent visits
during the 12-month study (Figure 4). A total of 213
participants completed the dose-optimization phase and
were classified as symptomatic remitters at entry to the
maintenance phase. In addition, 140 (65.7%) partici-
pants, of which not all completed each study visit
(ie, ET), did not experience a loss of symptomatic remis-
sion during the maintenance phase or at each of their









Figure 3 Percentage of participants optimized to each dose,
among participants who completed dose optimization (n=327).
Percentages have been rounded; total tally may not equal 100%.
Abbreviations: d=day; LDX=lisdexamfetamine dimesylate.Safety
Safety data were previously reported in detail for the
short- and long-term studies [5,20]. In the short-term
study, 5.9% of participants discontinued due to TEAEs
in the LDX group, and 1.6% in the placebo group. In the
long-term study, 8.0% of participants discontinued due
to TEAEs. In the short-term study, TEAEs were reported
by 79% of participants taking LDX and 58% taking pla-
cebo. In the long-term study, TEAEs were reported in
87.7% of participants. TEAEs reported by >10% of parti-
cipants with LDX treatment in the short-term study
included decreased appetite (27%), dry mouth (26%),
headache (21%), and insomnia (19%) and in the long-
term study included upper respiratory tract infection
(22%), insomnia (20%), headache (17%), dry mouth
(17%), decreased appetite (14%), and irritability (11%). In
both trials, the majority of AEs were mild or moderate
in severity.
Discussion
Limited data exist on how to monitor and optimize
treatment in adults with ADHD. We propose that a
30% reduction on the ADHD-RS-IV along with a 1- to
2-point improvement in CGI is a useful measure of ini-
tial clinical response. Even more importantly, a score of
18 or less on the ADHD-RS-IV (the 18 symptoms of
ADHD are mild or less on average) appears to be a real-
istic goal for ADHD treatment in adults. These post hoc
analyses of data from a short-term study [5] and a long-
term study [20] have shown that LDX in adults with
ADHD is associated with clinical response and symp-
tomatic remission that persist over time for many parti-
cipants. In the 4-week study, the majority of participants
met post hoc criteria for clinical response and nearly half
met criteria for symptomatic remission. In the 12-month
study, nearly all dose-optimized participants (95.7%) met
criteria for clinical response and many participants
(85.0%) met criteria for symptomatic remission at least
once during the trial. Of the participants who met cli-
nical response criteria, 75.2% continued to meet criteria
at every subsequent visit, and of those who met symp-
tomatic remission criteria, nearly two-thirds (65.7%)
continued to meet symptomatic remission criteria at all
subsequent visits.
In adults with ADHD, there are not many recognized
and clinically relevant measures that have been estab-
lished. Similar to treatment guidelines for major depres-
sion that have emphasized the importance of treating to
levels of symptomatic remission, describing criteria for
clinical response and symptomatic remission in adults
with ADHD may provide a useful, clinically relevant
measure. This may be more meaningful to clinicians
than are assessments of group average scores and popu-
lation norms on symptom rating scales, most of which
Table 3 Clinical response and symptomatic remission outcomes in the long-term study among participants who
completed dose optimization, by optimized dose (n=327)
LDX
30 mg/d (n=44) 50 mg/d (n=112) 70 mg/d (n=171) All Doses (n=327)
Clinical response, n (%) 42 (95.5) 107 (95.5) 164 (95.9) 313 (95.7a)
Symptomatic remission, n (%) 38 (86.4) 95 (84.8) 145 (84.8) 278 (85.0b)
aSee Figure 4.
bSee Figure 5.
Abbreviation: LDX lisdexamfetamine dimesylate.
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clinical response and symptomatic remission provides
clinicians with outcome measures that resemble clinical
approaches to patient assessment and treatment [18].
Applying these criteria in clinical practice will offer a
useful assessment measure with benchmarks for optimal
treatment. Time to median clinical response and symp-
tomatic remission informs both the participant and the
clinician about when noticeable therapeutic effects could
be expected to emerge for most patients, setting the
stage for more timely recognition of a need for dose
optimization or medication switching. In the short-term



























Figure 4 Percentage of participants who achieved clinical response a
(inset) of attainment (a) and loss (b) of clinical response from baselin
attainment (a), log rank P-value: .0115; time to first clinical response was ca
maintenance phase of the study (n=327), response status at the start of the
assessment of Attention-Deficit/Hyperactivity Disorder Rating Scale IV and C
indicates overall significant effect among the treatment groups and was no
log rank P-value: .5531; time to loss of clinical response during the mainten
response (n=278) at week 4 (visit 5); P-value indicates overall significant eff
between any individual dose groups. Abbreviation: LDX=lisdexamfetamineachieved by most participants in approximately 2 weeks.
Due to the forced-dose escalation design of the 4-week
study, however, it is not possible to differentiate the rela-
tive contributions of dose level versus time on treatment
for achieving clinical response criteria.
A number of investigators have described clinical re-
sponse and symptomatic remission rates for stimulant
and nonstimulant pharmacotherapy in adults with
ADHD. In previous trials of adults with ADHD, clinical
response has been defined either as at least a 30% de-
cline from baseline in symptom scores on a validated
rating scale of adult ADHD symptom severity [6,23,24]
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Figure 5 Percentage of participants who achieved symptomatic remission and maintained symptomatic remission and Kaplan-Meier
time course (inset) of attainment (a) and loss (b) of symptomatic remission in the long-term study for all LDX treatment groups. For
attainment (a), log rank P-value: .0012; time to first symptomatic remission was calculated from the first day of the study for participants who
entered the maintenance phase of the study (n=327), remission status at the start of the long-term study was not determined, and first on-
treatment assessment of Attention-Deficit/Hyperactivity Disorder Rating Scale IV was at week 1; P-value indicates overall significant effect among
the treatment groups and was not specifically tested between any individual dose groups. For loss (b), log rank P-value: .0385; time to loss of
symptomatic remission during the maintenance phase was calculated for participants who met criteria for remission (n=213) at week 4 (visit 5);
P-value indicates overall significant effect among the treatment groups and was not specifically tested between any individual dose groups.
Abbreviation: LDX=lisdexamfetamine dimesylate.
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using variable dosing designs have been conducted with
other long-acting psychostimulants (besides LDX) in
adults with ADHD. Clinical response rates ranged from
48.5% to 95.1% [3,4,6,23-25]. No previous reports have
explicitly described symptomatic remission in adults
with ADHD. Adler et al. [25] described the proportions
of “normal to mildly ill” adults with ADHD based on
endpoint CGI-S ratings; 64.6% met those criteria in the
5-week, short-term double-blind treatment phase (fixed
dose of d-MPH extended release). In the open-label ex-
tension phase, 90.0% who switched from placebo and
92.7% who continued on active treatment met those cri-
teria. Jain and colleagues [4] described participants with
“normalization rates. . .[of] 73.7%” based on Conners’
Adult ADHD Rating Scales–Self Report Index T-scores
of <65, which indicates that the severity of impairment
is below clinical threshold levels. In the current analysis,
85.0% of participants in the long-term trial met the cri-
teria for symptomatic remission; in 65.7% of these parti-
cipants, symptomatic remission persisted with continued
treatment. Study design differences may account for the
broad variability seen among these trial outcomes.Importantly, definitions of clinical response and symp-
tomatic remission varied widely, which is understood
to lead to different outcomes [12,15,18]. Neither the
current trial nor prior investigations have conducted
head-to-head treatment comparisons, precluding mea-
ningful comparisons of clinical response and symptom-
atic remission rates between treatments.
The criteria for clinical response used in this post hoc
analysis were more stringent than most existing reports
because they required improvement as assessed by 2
separate measures: ADHD-RS-IV with adult prompts
and the CGI-I. This double-measure criterion is not
without precedent. It has been used previously in adults
with ADHD in a trial of osmotic-release oral system
MPH [3]. Most trials, however, have defined clinical re-
sponse based on a single measure, such as Medori and
colleagues [24]. Several factors argue against a single
cutoff criterion. For example, recent research has shown
that, in adults, a 25% to 30% change from baseline to
endpoint in ADHD-RS-IV score or an absolute change
of approximately 10 to 15 points corresponds to a
change of one level in CGI-I rating in both adults and
children, [14] and this may not be clinically meaningful.
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is not sufficient because participants who are severely ill
at baseline may still exhibit significant symptoms [12].
Addition of the CGI-I criterion of 1 or 2, as applied in
the current study, prevents such participants from being
defined as clinical responders. The criteria for sympto-
matic remission applied in the current study are consis-
tent with some definitions previously proposed for
symptomatic remission [18,19] and represent a substan-
tial treatment-associated decrease of symptoms, but they
do not preclude the ongoing presence of mild residual
symptoms that are not disabling. Further studies are
required to validate this concept of symptomatic remis-
sion and its relationship to daily functioning and ADHD
diagnostic threshold.
The application of different criteria for clinical response
and symptomatic remission could lead to different results
[15]. These classifications of clinical response and symp-
tomatic remission are based on a current symptom scale
and do not purport to reflect functional outcomes or other
measures that may be used to characterize clinical im-
provement or recovery in a disease state. Recent studies
[26,27] have focused on looking beyond symptom assess-
ment to a more comprehensive understanding of func-
tional outcomes and the real-world impact of symptom
severity and treatment-related improvements [27]. For
example, a combined analysis of randomized participants
from 4 different studies that pooled participants across
treatment groups suggested that a reduction of approxi-
mately 20 points on the ADHD-RS was associated with
pronounced functional outcome improvement (social and
behavioral) on the Life Participation Scale [28]. This result
corresponded to a 50% to 65% improvement in symptom
severity levels and demonstrated improvement in func-
tional outcome status. The analysis also indicated that a
threshold of 40% to 45% improvement in symptom sever-
ity was needed to achieve clinically apparent functional
improvement [28]. Diagnostic criteria for ADHD in adult
patients and the criteria for clinical response and symp-
tomatic remission in these post hoc analyses were based
on those listed in the DSM-IV-TR. Although changes in
symptom thresholds of the diagnostic criteria may occur
with the expected adoption of the revised version, DSM 5
in 2013, current considerations maintain the requirement
for 6 symptoms of either subtype to diagnose ADHD in
adults [29]. Pending implementation of potential changes,
it may be interesting for future analyses to examine the
impact of revised criteria for symptom presentation on
clinically relevant assessments of clinical response and
symptomatic remission.
Limitations
There were several limitations of the current studies and
analyses. This publication is derived from post hocanalyses rather than predefined study endpoints. Both
the short- and the long-term investigations excluded adult
participants with common medical and psychiatric comor-
bidities; hence, current findings may not generalize to a
broader clinical population. The use of a forced-dose
escalation design in the short-term study may have led to
nonrandom participant discontinuation (eg, possible poor
tolerability in higher dose groups and lack of efficacy in
lower dose groups). As in other trials that use open-ended
questioning and spontaneous report to collect data on
AEs, incidence may be underreported. In interpreting the
findings on maintenance of response and remission in the
long-term study, one should keep in mind that dose
changes were possible for each individual during the
maintenance phase of the study and, as such, may have
contributed to maintenance of response and remission.
The long-term study was open label, introducing the
potential for investigator and participant bias toward
reporting clinical improvement and, as with other long-
term studies, participants leave over the course of the
study for various reasons.
The criteria for response and remission were based on
assessment of global and individual symptom level and
severity. The impact of treatment on other important
facets of ADHD, such as quality of life, or functional re-
covery/remission cannot be addressed. Although ana-
lyses evaluating participants who did not respond to
treatment or who failed to maintain clinical response to
treatment would be quite interesting and informative, it
is beyond the scope of the current analysis. Also, not all
participants respond to psychostimulant treatments, in-
cluding LDX. Future work could examine characteristics
and/or predictors of clinical nonresponse.
A limitation in interpreting time to occurrence of a spe-
cific event (in this study the event is defined as either loss
of response or remission status) using the Kaplan-Meier
survival analysis approach involves the process of censor-
ing (removing) participants from the analysis. Participants
are censored (removed) from the analysis if they have not
had the event (eg, achieved response or remission status),
and are no longer available to observe for the event. This
occurred at the end of the study period, and when partici-
pants discontinued or were lost to follow-up while still a
responders/remitters at their last visit. Therefore when we
report that of 278 participants experiencing a clinical re-
sponse on entering the maintenance phase of the study;
209 did not lose that response during their participation,
not all had completed the study.
Conclusions
The majority of adults receiving LDX achieved clinical
response (ADHD-RS-IV total score reduction of ≥30%
and a CGI-I rating of 1 or 2) within 15 days of initiating
therapy during the short-term trial. The majority of
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mission (ADHD-RS-IV total score of ≤18%) during the
long-term, open-label, dose-optimization trial, and more
than half maintained remitted status throughout contin-
ued LDX treatment. In order to confirm these results,
prospective evaluation of clinical response and symp-
tomatic remission endpoints is needed in future investi-
gations. The safety profile of LDX was consistent with
that of other long-acting psychostimulants.
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